Virtu Financial LLC Makes New $1.59 Million Investment in BioNTech SE (NASDAQ:BNTX)

Virtu Financial LLC bought a new position in BioNTech SE (NASDAQ:BNTX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 19,742 shares of the company’s stock, valued at approximately $1,586,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale raised its holdings in BioNTech by 3.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 427,597 shares of the company’s stock worth $34,533,000 after purchasing an additional 15,700 shares in the last quarter. Daiwa Securities Group Inc. grew its position in shares of BioNTech by 430.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after buying an additional 1,562 shares during the period. Choreo LLC bought a new position in shares of BioNTech in the 2nd quarter worth about $690,000. Caprock Group LLC purchased a new position in BioNTech during the 2nd quarter valued at about $206,000. Finally, Gallacher Capital Management LLC boosted its stake in BioNTech by 12.1% during the second quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company’s stock worth $294,000 after acquiring an additional 395 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX stock opened at $124.71 on Wednesday. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $88.13 and a 200-day moving average price of $89.90. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a market capitalization of $29.65 billion, a PE ratio of 249.42 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The company had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company’s revenue for the quarter was down 23.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.86) EPS. As a group, equities research analysts expect that BioNTech SE will post -2.8 earnings per share for the current year.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $113.00 target price on shares of BioNTech in a research note on Monday. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and upped their price target for the stock from $96.00 to $150.00 in a research note on Tuesday. TD Cowen lowered their price objective on BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Bank of America boosted their target price on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday. Finally, JPMorgan Chase & Co. upgraded BioNTech from an “underweight” rating to a “neutral” rating and raised their price target for the company from $91.00 to $125.00 in a report on Monday. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.00.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.